Tahir Khwaja, MD
Child & Adolescent Psychiatry · North Brunswick, NJNPI 1881804938
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $4,900 with a category attached, or 61.2%. Brainsway USA Inc accounts for 61.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $3,185 and has fallen 88.2% since, to $374 in 2025. Among child & adolescent psychiatry clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $116.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainsway USA Inc$3K
- Neuronetics, Inc.$1K
- Johnson & Johnson$162
- Teva Pharmaceuticals USA, Inc.$145
- Otsuka America Pharmaceutical, Inc.$125
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115
- plus $273 from 7 others
Across 9 payments — averaging $5963.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$24K
- Teva Pharmaceuticals USA, Inc.$15K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$15K
What the payments were for
- Speaking & faculty fees$3,00061%
- Food & beverage$1,85238%
- Education$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainsway USA Inc | 2 | $3,013 |
| Neuronetics, Inc. | 9 | $1,068 |
| Johnson & Johnson | 6 | $162 |
| Teva Pharmaceuticals USA, Inc. | 4 | $145 |
| Otsuka America Pharmaceutical, Inc. | 6 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $115 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Almatica Pharma LLC | 1 | $27 |
| Noven Therapeutics, LLC | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Alkermes, Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,900 in reported general payments places this provider in the 90th percentile of 137 child & adolescent psychiatry providers in New Jersey.
See all child & adolescent psychiatry providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate Hcl | 11 | $407 |
| Clonazepam | 27 | $193 |
| Alprazolam | 26 | $145 |
| Lorazepam | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in North Brunswick
- Ravinder BhallaRidgewood$125K
- Steven DyckmanEast Brunswick$53K
- Eric BartkyLivingston$51K
- Bohdan CzartoryskyParsippany$21K
- Akhtar HossainSomerville$19K
- Suzanne LindNew Brunswick$18K
- Aykut OzdenEdgewater$17K
- Valeria KorshunovaHackensack$12K
- Carol DobrzynskiBrick$10K
- Saranga BhallaPrinceton$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.